



# LES « BATTLES » DU CFP

## **Médecine personnalisée**

**N. Dusetti (Marseille)**

## **Nouvelles cibles thérapeutiques**

**P. Cordelier (Toulouse)**



## LES « BATTLES » DU CFP

**Médecine personnalisée**  
N. Dusetti (Marseille)

# Pancreatic Cancer Heterogeneity

Inter-tumoral heterogeneity

## Histological characteristics

### Survival time after diagnosis


<3 months to >5 years

### Response to gold standard treatments


10% to Gemcitabine

35% to Folfirinox


Targeted therapies  
Mainly BRCAness,  
MSI et fusions



**Poor  
differentiated**



**Intermediate**



**Well  
differentiated**

- Same treatment for all patients
- Personalizing treatments (essential!)

# Pancreatic Cancer Heterogeneity


Inter-tumoral heterogeneity

## Histological characteristics


**Survival time after diagnosis**  
<3 months to >5 years

**Response to gold standard treatments**  
**10% to Gemcitabine**  
**35% to Folfirinox**


**1/ New drugs against PDAC**  
**2/ Treatments personalization**



**Poor  
differentiated**




**Intermediate**




**Well  
differentiated**

# Treatments personalization





# Transcriptome-associated to anticancer drug sensibility





# Retrospective clinical study in resected tumors



(Prodige 24: 349 PDAC patients)



# Retrospective clinical study in metastatic patients (GemPredRetro: 106 PDAC patients)




Biopsies from  
primary tumors



Biopsies from  
metastasis



# Platform of chemosensitivity prediction




# Clinical trial: Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures (PACsign)

*Sponsor Institut:* Curie Saint-Cloud  
*Study Director:* Cindy NEUZILLET

Hôpital Beaujon, Clichy  
Louis DE MESTIER

Hôpital Claude Hurriez Lille  
Antony TURPIN



Estimated Study Start Date :	September 30, 2022
Estimated Primary Completion Date :	January 30, 2024
Estimated Study Completion Date :	March 30, 2025

# Nouvelles cibles thérapeutiques

Très important mais pas avant plusieurs années

# Médecine personnalisée

immédiatement



# **Médecine personnalisée**

**des traitements actuels et  
des nouvelles cibles  
thérapeutiques**

***Votez Nelson!***

